

12

PROGRESS IN CARDIOLOGY

Edited by

PAUL N. YU, M.D.

*Sarah McCort Ward Professor of Medicine,
University of Rochester School of Medicine and Dentistry,
Rochester, New York*

and

JOHN F. GOODWIN, M.D.

*Professor of Clinical Cardiology,
Royal Postgraduate Medical School,
London, England*



LEA & FEBIGER · Philadelphia, 1983

Lea & Febiger
600 Washington Square
Philadelphia, Pa. 19106
U.S.A.

OTHER BOOKS IN THE SERIES

Progress in Cardiology 1—1972—\$15.00
Progress in Cardiology 2—1973—\$15.00
Progress in Cardiology 3—1974—\$17.50
Progress in Cardiology 4—1975—\$15.00
Progress in Cardiology 5—1976—\$19.50
Progress in Cardiology 6—1977—\$15.00
Progress in Cardiology 7—1978—\$17.00
Progress in Cardiology 8—1979—\$25.00
Progress in Cardiology 9—1980—\$15.00
Progress in Cardiology 10—1981—\$38.50
Progress in Cardiology 11—1982—\$30.00

The Library of Congress has cataloged this serial
publication as follows:

Progress in cardiology. 1—

Philadelphia, Lea & Febiger, 1972—

v. ill. 26 cm. annual.

ISSN 0097-109X

1. Cardiology—Periodicals.

RC681.A1P74 616.1'2'005 77-157474

ISBN 0-8121-0326-2 (v. 1)
ISBN 0-8121-0409-9 (v. 2)
ISBN 0-8121-0451-X (v. 3)
ISBN 0-8121-0509-5 (v. 4)
ISBN 0-8121-0578-8 (v. 5)
ISBN 0-8121-0596-6 (v. 6)
ISBN 0-8121-0621-0 (v. 7)
ISBN 0-8121-0694-6 (v. 8)
ISBN 0-8121-0728-4 (v. 9)
ISBN 0-8121-0815-9 (v. 10)
ISBN 0-8121-0855-8 (v. 11)
ISBN 0-8121-0911-2 (v. 12)

Copyright © 1983 by LEA & FEBIGER, Copyright under the International Copyright Union. All Rights Reserved. *This book is protected by copyright. No part of it may be reproduced in any manner or by any means without written permission from the publisher.*

Printed in the United States of America

Print No. 3 2 1

12

PROGRESS IN CARDIOLOGY

PREFACE

Cardiovascular imaging using radionuclides has become an important diagnostic modality in cardiovascular medicine. We believe that it is timely and appropriate to review the progress in this field. We are privileged and pleased to invite Dr. George Beller to serve as the guest editor of a Symposium on Cardiovascular Imaging that includes contributions from a number of distinguished investigators who discuss recent advances in this area.

Dr. Beller writes a thoughtful and stimulating foreword in which he presents an overview of cardiovascular imaging in 1983 and summarizes the contents of the first six chapters of the book.

The second half of the book contains six chapters that cover other aspects of cardiovascular disease, contributed by investigators from the U.S.S.R., United Kingdom, Japan, Switzerland, and the U.S.A.

In Chapter 7 Professor Eugene Chazov describes the work of the U.S.S.R. Cardiology Research Center dealing with the role

of changes in the arterial wall in the genesis of atherosclerosis and thrombosis. Starting with the assumption that the patchy nature of atherosclerotic plaques suggests an abnormality in the vessel wall rather than circulating factors such as lipids as a primary cause, Professor Chazov details the results of tissue culture studies of arterial wall cells, endothelial, and subendothelial layers. He presents data suggesting that "foam cells" are derived from arterial smooth muscle cells, and compares the characteristics of normal, early, and later atherosclerotic lesions with regard to proliferative activity and handling of low-density lipoproteins (LDL). Two populations of plasma cells, one with high rates of incorporation of LDL and the other with low rates of incorporation, are described. High-density lipoproteins (HDL) added to cultures of cells with lipid inclusions decreased the number of these cells but did not have the same effect on cells from the plaque. Studies of perfused arteries showed that HDL partially inhibited LDL

uptake in normal vascular areas but had no effect on the endothelialized zone. Professor Chazov and his colleagues conclude that an intact endothelial sheet is the site of the anti-atherogenic action of HDL.

To those who are interested in the study of the cause of atherosclerosis, this chapter concentrates on the arterial wall but does not ignore other factors such as lipids and platelets. The chapter is also supported by an extensive bibliography.

In Chapter 8 Drs. Emanuel and Withers discuss the genetics of hypertrophic and dilated (congestive) cardiomyopathy. They describe their studies of 97 index cases of hypertrophic cardiomyopathy (HCM). They have examined the relationship of HCM to asymmetric septal hypertrophy (ASH) and conclude that the simplest genetic concept would be a single autosomal dominant gene that could be expressed in a mild (isolated ASH) or severe (HCM) form. The authors feel that this concept alone would not account for the presence of extremes within one family. Perhaps a gene for ASH could be expressed as HCM as a result of genetic or environmental modifications, or a gene for HCM could, with other genetic and environmental modifications, be expressed as ASH. The authors conclude that HCM is an autosomal dominant condition but suggest that the presence of modifying genes gives a polygenic threshold character to the presentation of the disorder. Their polygenic model requires an underlying continuously varying predisposition or liability to a disease that includes several genetic and environmental factors. Thus, above a certain threshold subjects show clinical evidence of HCM, and below this they show evidence only of ASH.

The authors also comment on work with the Syrian hamster with regard to dilated cardiomyopathy, and the possibility that a genetic predisposition might determine the development of dilated cardiomyopathy from virus myocarditis. The place of HLA antigens in hypertrophic and dilated cardiomyopathy is discussed, and it is suggested

that HLA studies so far have been inconclusive. A study of phenotypes in molecular terms is needed before further advances are likely to be made. This chapter admirably summarizes what is and is not known in this important field of cardiovascular genetics.

In Chapter 9, Dr. Kawai and associates summarize the recent advances in the study of hypertrophic and dilated (congestive) cardiomyopathy. In hypertrophic cardiomyopathy (HCM), the characteristic features and mechanisms of left ventricular inflow obstruction, hyperdynamic ventricular contraction, diastolic properties, and filling of the left ventricle are reviewed. Immunogenetic analysis with new information gained from HLA studies in patients with HCM and studies of infectious-immune mechanism in experimental dilated cardiomyopathy may shed some light on the pathogenesis of cardiomyopathies. Biochemical studies of myocardial metabolism in patients as well as in animals have become increasingly important in elucidating the pathogenesis, structure, and function of both clinical and experimental cardiomyopathies.

There is currently no specific therapy for either hypertrophic or dilated cardiomyopathy. Beta-adrenergic blocking agents, calcium channel blocking agents, vasodilators, antiarrhythmic agents, and synthetic catecholamines, however, have been used successfully in relieving the symptoms, improving ventricular function, and possibly prolonging the lives of these patients.

In Chapter 10 Drs. Gersbach and Hahn report on their extensive experience in over 2,000 coronary endarterectomies in a group of 6,411 patients with coronary artery disease who underwent operations between 1968 and 1982. Surgical techniques, sites, and characteristics of the endarterectomies are described. The results of the endarterectomies, including mortality rate, five-year and ten-year survival rates, and perioperative infarction rates, are analyzed. The patency rate of bypass grafts is significantly

higher in patients with endarterectomy than in those without endarterectomy.

This is one of the largest reported series of coronary endarterectomies. The contributors' experience will be of great value to all readers, not because of differing views on the value and benefits of endarterectomy, but because of the excellent results in high-risk patients.

In Chapter 11 Dr. Frohlich reviews various aspects of antihypertensive therapy and lists the classification of the newer antihypertensive agents. Five groups are mentioned: diuretics, beta-adrenergic blocking agents, antiadrenergics, renin-angiotensin system inhibitors, and calcium antagonists. The newer diuretics include amiloride, indapamide, and bumetanide. Propranolol, metoprolol, atenolol, pindolol, nadolol and timolol are the six beta-adrenergic blocking drugs used in the U.S.A. There are three classes of antiadrenergics: centrally active agents, peripherally acting agents, and serotonin receptor antagonists. Captopril and enalapril are the two renin-angiotensin system inhibitors. Three calcium antagonists are available for clinical use: nifedipine, verapamil, and diltiazem.

In Chapter 12 Dr. Kennedy gives a report of the preliminary results of the Western Washington Intracoronary Streptokinase Trial in a series of 250 patients with acute myocardial infarction. This study involved the participation of 54 cardiologists in 14 different laboratories. Two groups of patients were included: (1) a treated group of 134 patients who received intracoronary streptokinase infusion, and (2) a control group of 116 patients who received no in-

fusion. Among all 250 patients, 86% had total occlusion and 14% had 90% stenosis of the coronary arteries serving the infarcted area when observed. angiographically an average of 274 minutes following the symptoms of acute myocardial infarction. The treated group of patients received an average of 272,000 units of intracoronary streptokinase over a period averaging 72 minutes. In two thirds of the totally occluded vessels reperfusion was achieved, and in over 80% of the stenotic vessels improved perfusion was observed following the infusion. During the first thirty days the mortality rate was 3.7% in the treated group and 11.6% in the control group. The difference was statistically significant. At the time of discharge the patients in the treated group had significantly fewer anginal attacks and improved functional class as compared to those in the control group. The two major complications of the streptokinase treatment were bleeding and ventricular arrhythmia. The author concludes there is reason to believe that early and effective coronary artery thrombolysis can reduce mortality and improve the course of patients with acute myocardial infarction.

We wish to express our thanks and appreciation to the staff of Lea & Febiger: Mr. R. Kenneth Bussy, Mr. Francis C. Lea, Mr. Thomas J. Colaiezzi, Mr. Lawrence Bentley, Mrs. Holly Campbell Lukens and Ms. Constance Marino. We are also indebted to Miss Cheryl Peacock, Mrs. Sharon Postwick and Mrs. Elizabeth Bashford for their secretarial assistance.

Rochester, New York
London, England

Paul N. Yu
John F. Goodwin

CONTRIBUTORS

George A. Beller, M.D.
Professor of Medicine
Chief of Cardiology Division
University of Virginia School of Medicine
Charlottesville, Virginia

Harvey J. Berger, M.D.
Associate Professor of Diagnostic Radiology and
Internal Medicine
Director of Cardiovascular Imaging Laboratory
Yale University School of Medicine
New Haven, Connecticut

Charles A. Boucher, M.D.
Assistant Professor of Medicine
Harvard Medical School
Assistant Physician
Cardiac Unit
Massachusetts General Hospital
Boston, Massachusetts

Eugene I. Chazov, M.D.
Director of USSR Cardiology Research Center
USSR Academy of Medical Sciences
Moscow, USSR

Richard Emanuel, M.D.
Lecturer, Cardiothoracic Institute
London University
Physician
National Heart Hospital
Senior Physician, Cardiac Department
The Middlesex Hospital
London, England

Edward D. Frohlich, M.D.
Vice President of Education and Research
Alton Ochsner Medical Foundation
Member of Section of Hypertensive Diseases
Ochsner Clinic
New Orleans, Louisiana

Philippe A. Gersbach, M.D.
Resident in Cardiovascular Surgery
Genolier Clinic
Genolier, Switzerland

Robert S. Gibson, M.D.
Assistant Professor of Medicine
Director of Cardiac Noninvasive Laboratory
University of Virginia Medical Center
Charlottesville, Virginia

Mark R. Goldman, M.D.
Consultant
MGH NMR Imaging Project
Newton-Wellesley Hospital
Newton, Massachusetts

Richard A. Goldstein, M.D.
Assistant Professor of Medicine
Director of Nuclear Cardiology Section
University of Texas Medical School
Houston, Texas

Lance K. Gould, M.D.
Professor and Director of Cardiology Division
Director of Positron Diagnostic Center
University of Texas Medical School
Houston, Texas

Charles Hahn, M.D.
Professor of Cardiovascular Surgery
University of Geneva
Chief of Cardiovascular Department A
Genolier Clinic
Genolier, Switzerland

Charles B. Higgins, M.D.
Professor of Radiology and Medicine
Chief of Clinical NMR
San Francisco Medical Center
University of California
San Francisco, California

Chuichi Kawai, M.D.
Professor of Medicine
Chief, Third Division
Department of Internal Medicine
Kyoto University Hospital
Kyoto, Japan

J. Ward Kennedy, M.D.
Professor of Medicine
Chief of Cardiology Division
University of Washington
Seattle, Washington

Akira Matsumori, M.D.
Professor of Medicine
Kyoto University
Research Fellow
Harvard Medical School
Faculty Staff, Third Division
Department of Internal Medicine
Kyoto University Hospital
Kyoto, Japan

G. B. Mancini, M.D.
Assistant Professor of Medicine
Division of Cardiology
University of Michigan
Staff Physician
Veterans Administration Medical Center
Ann Arbor, Michigan

Nizar A. Mullani, M.S.
Assistant Professor of Medicine
Director of Physics Section
Technical Director of Positron Diagnostic
Research Center
University of Texas Medical School
Houston, Texas

S. L. Norris, M.D.
Research and Clinical Scholar of Medicine
University of Southern California
Los Angeles, California

Robert D. Okada, M.D.
Assistant Professor of Medicine
Harvard Medical School
Assistant in Medicine
Cardiac Unit
Massachusetts General Hospital
Boston, Massachusetts

Gerald M. Pohost, M.D.
Professor of Medicine and Radiology
Director of Cardiology
University of Alabama Medical Center
Birmingham, Alabama

Adam J. Ratner, B.A.
Fellow
The Stanley J. Sarnoff Society of Fellows for
Cardiovascular Research
University of Texas Southwestern Medical School
Dallas, Texas

Tsunetaro Sakurai, M.D.
Professor of Medicine
Kyoto University
Faculty Staff, Third Division
Department of Internal Medicine
Kyoto University Hospital
Kyoto, Japan

Shigetake, Sasayama, M.D., F.A.C.C.
Professor of Medicine
Second Department of Internal Medicine
Toiyama Medical and Pharmaceutical University
Toiyama, Japan

Robert A. Slutsky, M.D.
Associate Clinical Professor of Radiology
University of California Medical Center
Consultant Radiologist
Veterans Administration Medical Center
San Diego, California

Denny D. Watson, Ph.D.
Professor of Radiology
Noninvasive Laboratory
University of Virginia Hospital
Charlottesville, Virginia

Ronald Withers, M.Sc.
Senior Lecturer in Human Genetics
Department of Anatomy and Biology as Applied to
Medicine
The Middlesex Hospital School
London, England

Yoshiki, Yui, M.D.
Professor of Medicine
Faculty Staff, Third Division
Department of Internal Medicine
Kyoto University Hospital
Kyoto, Japan

Barry L. Zaret, M.D.
Professor of Medicine and Diagnostic Radiology
Chief of Cardiology Section
Yale University School of Medicine
New Haven, Connecticut

CONTENTS

SYMPOSIUM ON NUCLEAR CARDIOLOGY

FOREWORD: AN OVERVIEW OF CARDIOVASCULAR IMAGING IN 1983 1
(George A. Beller)

1. RADIONUCLIDE ANGIOGRAPHY IN VALVULAR HEART DISEASE 5
(Charles A. Boucher, M.D., and Robert D. Okada, M.D.)

 Pathophysiologic Principles in Valvular Heart Disease 5

 Preload and Afterload 5

 Compensatory Mechanisms 6

 Acute versus Chronic Valvular Disease 7

 Heart Failure versus Systolic Function 7

 Atrioventricular Valve Regurgitation Due to Ventricular Dysfunction 8

 Postoperative Changes 8

 Radionuclide Assessment of Ventricular Function 10

 Qualitative Interpretation 10

 Ejection Fraction 11

 Left Ventricular Volumes 12

 Regurgitant Index 13

 Pulmonary Blood Volume Ratio 15

 Diastolic Properties 15

 Regional Wall Motion 15

 Clinical Applications 16

 Aortic Stenosis 17

 Mitral Stenosis 17

 Aortic Regurgitation 18

 Mitral Regurgitation 23

| | |
|--|---------------|
| Mitral Valve Prolapse | 24 |
| Pulmonic Stenosis | 24 |
| Tricuspid Regurgitation | 25 |
| Associated Coronary Artery Diseases | 25 |
| 2. RADIONUCLIDE STUDIES OF VENTRICULAR PERFORMANCE IN CORONARY ARTERY DISEASE | 33 |
| <i>(Barry L. Zaret, M.D., and Harvey J. Berger, M.D.)</i> | |
| Gated Equilibrium Cardiac Blood Pool Imaging | 34 |
| Instrumentation | 34 |
| Interpretation | 36 |
| Appearance of the Gated Blood Pool Study | 37 |
| Noncardiac Structures | 37 |
| Great Vessels | 38 |
| Right Atrium | 38 |
| Left Atrium | 38 |
| Right Ventricle | 38 |
| Left Ventricle | 39 |
| Left Ventricular Ejection Fraction | 40 |
| Additional Quantitative Measurements | 40 |
| Quantitative Analysis of Regional Wall Motion | 41 |
| Nonimaging Nuclear Probe | 42 |
| First-Pass Radionuclide Angiocardigraphy | 43 |
| Instrumentation | 44 |
| Interpretation | 45 |
| Regional Left Ventricular Performance | 47 |
| Comparison Between the First-Pass and Equilibrium Techniques | 47 |
| Factors Associated with Errors in Left Ventricular Ejection Fraction | 48 |
| Overestimation | 48 |
| Underestimation | 49 |
| Exercise Radionuclide Studies | 49 |
| Diagnosis of Coronary Artery Disease | 51 |
| Comparison of Exercise Radionuclide Diagnostic Techniques | 55 |
| Diagnosis of Resting Ventricular Dysfunction | 58 |
| 3. CLINICAL APPLICATIONS OF MYOCARDIAL PERFUSION SCINTIGRAPHY WITH THALLIUM-201 | 67 |
| <i>(Robert S. Gibson, M.D., and Denny D. Watson, Ph.D.)</i> | |
| Kinetics of Thallium Distribution and Redistribution | 67 |
| Initial Distribution of Thallium | 68 |
| Redistribution of Thallium | 68 |
| Delayed Distribution of Thallium | 71 |
| Technique | 71 |
| General Considerations and Exercise Stress | 72 |
| Dipyridamole Test | 73 |
| Imaging Procedure | 74 |
| Instrumentation | 75 |

| | |
|--|-----|
| Computer Processing for Quantitative Analysis of Plane Images | 75 |
| Computer Reconstruction Techniques | 78 |
| Clinical Interpretation | 79 |
| Normal Image Patterns | 79 |
| Abnormal Image Patterns for Specific Coronary Arteries | 80 |
| Type of Perfusion Abnormality | 82 |
| Nonperfusion Scintigraphic Parameters | 82 |
| Anatomic Variants | 83 |
| Perfusion Defects Without Angiographic Coronary Artery Disease | 85 |
| Clinical Applications | 85 |
| Detection of Coronary Artery Disease | 85 |
| Sensitivity and Specificity | 86 |
| Statistical Considerations and Bayes' Theorem | 87 |
| Practical Application of Exercise Tl-201 Scintigraphy to Detect Coronary Artery Disease | 90 |
| Asymptomatic Patients | 90 |
| Patients with Nonanginal Chest Pain | 92 |
| Patients with Atypical Angina Pectoris | 92 |
| Patients with Typical Angina Pectoris | 93 |
| Patients with Nondiagnostic Exercise Electrocardiograms | 94 |
| Evaluation of the Extent and Severity of Coronary Artery Disease | 94 |
| Role of Coronary Angiography | 94 |
| Location and Extent of Coronary Artery Disease | 95 |
| Functional Significance of Anatomic Stenoses | 96 |
| Functional Significance of Collateral Coronary Vessels | 97 |
| Evaluation of Myocardial Viability | 97 |
| Evaluation of Surgical Therapy | 100 |
| Evaluation of Thrombolytic Therapy | 101 |
| Use in Acute Myocardial Infarction | 101 |
| Use in Estimating Prognosis | 102 |
| Summary and Future Considerations | 106 |

4. DIGITAL SUBTRACTION ANGIOGRAPHY: TECHNIQUE AND CARDIAC APPLICATIONS

113

(Charles B. Higgins, M.D., G.B. John Mancini, M.D., Sharon L. Norris, M.D.,
and Robert A. Slutsky, M.D.)

| | |
|---|-----|
| Technical Considerations | 113 |
| Contrast Enhancement | 114 |
| Filtering | 114 |
| Subtraction | 115 |
| System Specifications for Cardiac Studies | 116 |
| Technique for Clinical Studies | 117 |
| Left Ventricular Dimension | 117 |
| Regional Left Ventricular Function | 118 |
| Geometric Technique | 127 |
| Functional Images | 127 |
| Parametric Images | 129 |

| | |
|--|-----|
| Evaluation of Response to Interventions | 129 |
| Evaluation of Coronary Artery Bypass Grafts | 131 |
| Limitations of Digital Subtraction Angiography and Comparison With Other Cardiac Imaging Techniques | 131 |
| 5. PROTON NUCLEAR MAGNETIC RESONANCE IMAGING OF THE HEART | 135 |
| <i>(Adam V. Ratner, Gerald M. Pohost, M.D., Mark R. Goldman, M.D., and Robert D. Okada, M.D.)</i> | |
| Physical Principles of Nuclear Magnetic Resonance | 135 |
| Cardiac NMR Imaging Techniques | 139 |
| Utility of NMR Imaging of the Heart | 140 |
| Evaluation of Cardiac Structure and Function | 142 |
| Evaluation of Myocardial Disease | 142 |
| Paramagnetic Contrast Agents and Perfusion Imaging | 143 |
| High-Speed Imaging | 144 |
| Imaging of Other Nuclei | 144 |
| Potential Hazards of NMR | 144 |
| Clinical Impact of Cardiovascular NMR Techniques | 145 |
| 6. QUANTITATIVE MYOCARDIAL IMAGING WITH POSITRON EMITTERS | 147 |
| <i>(Richard A. Goldstein, M.D., Nizar A. Mullani, M.S., and K. Lance Gould, M.D.)</i> | |
| Physics | 147 |
| Physical Properties of Single-Photon Emitters | 147 |
| Physical Properties of Positron Emitters | 148 |
| Dosimetry | 150 |
| Positron Cameras | 150 |
| Spatial Resolution | 152 |
| Temporal Resolution | 154 |
| Sensitivity | 154 |
| Coincidence Resolving Time and Random Counts | 155 |
| Physiologic Gating | 156 |
| Number of Slices | 156 |
| Mechanical Specifications | 157 |
| Computing Specifications | 158 |
| Interpretation of the PET Data as Related to Camera Characteristics | 159 |
| Effect of Scatter | 161 |
| Effect of Random Coincidences | 161 |
| Effect of Statistical Noise | 162 |
| Attenuation Correction Errors | 162 |
| Partial Volume Errors | 163 |
| Effect of Relationship Between Image Resolution and Signal- Noise Ratio | 164 |
| Effect of Sensitivity and Resolution | 166 |
| Effect of Time-of-Flight Measurements | 167 |

| | |
|---|------------|
| Generation of Radionuclides | 169 |
| Modeling or Processing of Data for Physiologic Interpretation | 171 |
| Compartmental Analysis | 173 |
| Vascular Tracers | 173 |
| Vascular-Interstitial Tracers | 175 |
| Cellular Diffusible Tracers | 175 |
| Physical Trapping and Partially Trapped, Diffusible Tracers | 175 |
| Metabolic Tracers | 175 |
| Specific Applications of Positron Imaging | 176 |
| Myocardial Flow | 176 |
| Nitrogen-13 Ammonia | 177 |
| Oxygen-15 Labeled Water and Hemoglobin | 178 |
| Rubidium | 178 |
| Myocardial Metabolism | 180 |
| Carbohydrate Metabolism | 182 |
| Amino Acid Metabolism | 184 |
| Fatty Acid Metabolism | 185 |
| Current Role of Positron-Emission Imaging | 186 |
| Relation to Other Techniques | 186 |
| Summary | 187 |
| 7. ARTERIAL WALL IN ATHEROSCLEROSIS | 193 |
| (<i>E. I. Chazov, M.D.</i>) | |
| 8. GENETICS OF THE CARDIOMYOPATHIES | 211 |
| (<i>Richard Emanuel, M.D., and Ronald Withers, M.Sc.</i>) | |
| Genetic Factors in Hypertrophic Cardiomyopathy | 211 |
| Early Studies | 211 |
| Relationship with Asymmetric Septal Hypertrophy | 212 |
| Polygenic Model | 214 |
| Genetic Factors in Dilated Cardiomyopathy | 215 |
| Studies in the Syrian Hamster | 215 |
| Other Animal Studies | 218 |
| Summary | 220 |
| 9. RECENT ADVANCES IN THE STUDY OF HYPERTROPHIC AND DILATED (CONGESTIVE) CARDIOMYOPATHY | 225 |
| (<i>Chuichi Kawai, M.D., Shigetake Sasayama, M.D., Tsunetaro Sakurai, M.D., Akira Matsumori, M.D., and Yoshiki Yui, M.D.</i>) | |
| Definition and Classification of Cardiomyopathy | 225 |
| Ventricular Function in Hypertrophic Cardiomyopathy | 226 |
| Obstruction to Ejection | 226 |
| Asymmetric Septal Hypertrophy | 226 |
| Systolic Anterior Motion of Mitral Valve Leaflet | 227 |
| Midsystolic Closure of Aortic Valve | 227 |
| Distribution of Hypertrophy | 228 |
| Hyperdynamic Ventricular Contraction | 228 |
| Diastolic Property and Left Ventricular Filling | 229 |

| | |
|--|-----|
| Immunogenetic Analysis of Cardiomyopathy | 231 |
| Family 1 | 231 |
| Family 2 | 232 |
| Family 3 | 233 |
| Viral Infection and Immunologic Mechanisms in the Pathogenesis of Cardiomyopathy | 234 |
| Experimental Evidence for Acute Viral Myocarditis Causing Subsequent Cardiomyopathy | 234 |
| Animal Models of Dilated Cardiomyopathy | 235 |
| Factors Influencing Cardiomyopathy Due to Viral Infection | 235 |
| Immunopathogenesis of Viral Myocarditis | 237 |
| Immunologic Findings in Dilated Cardiomyopathy | 238 |
| Biochemical Analysis of Myocardial Metabolism in Cardiomyopathy | 238 |
| Cardiac Myosin and Myosin Isozyme | 238 |
| Calcium Metabolism | 240 |
| Catecholamine Metabolism | 240 |
| Defect in Membrane Composition | 240 |
| Lipid Metabolism | 241 |
| Nuclear Acidic Proteins | 241 |
| Treatment | 241 |
| Hypertrophic Cardiomyopathy | 241 |
| Dilated Cardiomyopathy | 243 |
| Summary | 244 |

10. CLINICAL EXPERIENCE IN OVER 2,000 ENDARTERECTOMIES: 1968 to 1982

249

(Philippe Gersbach, M.D., and Charles Hahn, M.D.)

| | |
|--|-----|
| Surgical Techniques | 250 |
| Results of Endarterectomy | 251 |
| Endarterectomized Vessel | 251 |
| Perioperative Mortality Rate | 251 |
| Survival Rates at 5 and 10 Years | 254 |
| Perioperative Infarction Rate | 254 |
| Follow-up at 1 Year | 254 |
| Discussion | 258 |
| Summary | 262 |

11. NEWER ANTIHYPERTENSIVE DRUGS

265

(Edward D. Frohlich, M.D.)

| | |
|--|-----|
| Classification of Therapy | 265 |
| Hemodynamic Orientation for Relating Antihypertensive Agents to Disease | 266 |
| Hemodynamic Concepts | 266 |
| Clinical Pharmacologic Concepts | 267 |
| New Concepts for Understanding Antihypertensive Therapy | 268 |
| Diuretics | 268 |
| Dose | 268 |

| | |
|--|-----|
| Hypokalemia | 268 |
| Dysrhythmias | 268 |
| Beta-Adrenergic Receptor Blocking Drugs | 269 |
| Cardioselectivity | 269 |
| Lipid Solubility | 270 |
| Intrinsic Sympathomimetic Activity (ISA) | 270 |
| Membrane Stabilizing Activity (MSA) | 270 |
| Antiadrenergics | 270 |
| Vasodilators | 271 |
| Reflex Responses | 271 |
| Fluid Retention | 271 |
| Angiotensin System Inhibitors | 272 |
| New Agents | 272 |
| Diuretics | 273 |
| Amiloride | 273 |
| Indapamide | 273 |
| Bumetanide | 273 |
| Beta-Adrenergic Receptor Blocking Drugs | 273 |
| Antiadrenergics | 275 |
| Centrally Active Agents | 275 |
| Peripheral Acting Agents | 276 |
| Serotonin Receptor Antagonists | 276 |
| Renin-Angiotensin System Inhibitors | 276 |
| Converting Enzyme Inhibitors | 276 |
| Calcium Antagonists | 278 |
| Summary | 278 |

12. THE INTRACORONARY STREPTOKINASE TREATMENT OF ACUTE MYOCARDIAL INFARCTION 283

(J. Ward Kennedy, M.D.)

| | |
|---|-----|
| The Pathophysiology of Acute Myocardial Infarction | 284 |
| Early Clinical Trials of Intravenous Streptokinase in Acute Myocardial Infarction | 285 |
| Observational Studies of Intracoronary Streptokinase Therapy | 286 |
| Randomized Studies of Intracoronary Streptokinase | 287 |
| Effect of Thrombolytic Therapy on Mortality | 287 |
| Complications of Intracoronary Streptokinase Therapy | 288 |
| Summary | 289 |